Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

640
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
640
Tissue Transplantation01:24

Tissue Transplantation

1.2K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.2K
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

488
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
488
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

529
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
529
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

578
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
578

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute myocardial infarction following allogeneic hematopoietic stem cell transplantation: A national cohort study.

Cancer letters·2026
Same author

Clinical Characteristics, Treatment Response, and Outcomes of Bronchiolitis Obliterans Syndrome in Children with Hematologic Malignancies Undergoing Haploidentical Hematopoietic Cell Transplantation with Granulocyte Colony-Stimulating Factor/Antithymocyte Globulin-Based Protocol: A Single-Center Study.

Transplantation and cellular therapy·2025
Same author

Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.

Bone marrow transplantation·2025
Same author

Tired of the confusion around pleural effusions: Adenosine deaminase detection sets the record straight!

World journal of clinical cases·2025
Same author

Incidence, Risk Factors, and Impact on Transplant Outcomes of Cytokine Release Syndrome After Infusion of Haploidentical Stem Cells With Anti-Thymocyte Globulin.

Clinical transplantation·2025
Same author

Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.

Haematologica·2025

Related Experiment Video

Updated: Mar 13, 2026

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

1.7K

Atorvastatin enhances endothelial cell function in posttransplant poor graft function.

Min-Min Shi1,2, Yuan Kong1, Yang Song1,2

  • 1Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, Peking University, Beijing, China; and.

Blood
|October 23, 2016
PubMed
Summary

Poor graft function after stem cell transplants is linked to dysfunctional endothelial progenitor cells (EPCs). Atorvastatin improved EPC number and function in vitro by targeting the p38 MAPK pathway, offering a potential therapy.

More Related Videos

Implantation of Electrospun Vascular Grafts with Optimized Structure in a Rat Model
08:46

Implantation of Electrospun Vascular Grafts with Optimized Structure in a Rat Model

Published on: June 27, 2018

8.6K
Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
06:14

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Published on: June 11, 2017

8.9K

Related Experiment Videos

Last Updated: Mar 13, 2026

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

1.7K
Implantation of Electrospun Vascular Grafts with Optimized Structure in a Rat Model
08:46

Implantation of Electrospun Vascular Grafts with Optimized Structure in a Rat Model

Published on: June 27, 2018

8.6K
Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
06:14

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Published on: June 11, 2017

8.9K

Area of Science:

  • Hematology
  • Cell Biology
  • Transplantation Immunology

Background:

  • Poor graft function (PGF) is a significant complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • Endothelial progenitor cells (EPCs) in the bone marrow (BM) microenvironment are crucial for supporting hematopoietic stem cells.
  • Previous research identified a reduced number of BM EPCs as a risk factor for PGF.

Purpose of the Study:

  • To evaluate the function of BM EPCs in patients experiencing PGF post-allo-HSCT.
  • To investigate the potential of atorvastatin to enhance the number and function of BM EPCs from PGF patients in vitro.

Main Methods:

  • Assessed proliferation, migration, angiogenesis, reactive oxygen species (ROS) levels, and apoptosis in BM EPCs from PGF patients.
  • Investigated the role of the p38 mitogen-activated protein kinase (MAPK) pathway and cyclic adenosine monophosphate-responsive element-binding protein (CREB) in PGF-derived BM EPCs.
  • Treated PGF-derived BM EPCs with atorvastatin in vitro to assess its effects on cell number and function.

Main Results:

  • BM EPCs from PGF patients exhibited impaired proliferation, migration, angiogenesis, and increased ROS and apoptosis.
  • Activation of p38 MAPK and CREB was observed in BM EPCs from PGF patients.
  • Atorvastatin treatment in vitro improved the number and function of BM EPCs from PGF patients by downregulating the p38 MAPK pathway.

Conclusions:

  • Dysfunctional BM EPCs are present in patients with PGF post-allo-HSCT.
  • Atorvastatin treatment in vitro enhances the quantitative and functional aspects of BM EPCs from PGF patients.
  • Atorvastatin shows promise as a therapeutic strategy for improving impaired BM EPCs in PGF patients.